We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 5 december 2017

The Lancet: [Comment] MiStent: just another example of non-inferiority?

[Comment] MiStent: just another example of non-inferiority?
The Xience everolimus-eluting coronary stent has been shown to reduce the risk for stent thrombosis and target-lesion revascularisation compared with first-generation drug-eluting stents.1 In recent trials of drug-eluting stents, several other new-generation stents, such as Resolute zotarolimus-eluting stent,2 Nobori biolimus-eluting stent,3 Synergy everolimus-eluting stent,4 Ultimaster sirolimus-eluting stent,5 and Orsiro sirolimus-eluting stent,6 were non-inferior to Xience for target-lesion failure; however, no new-generation drug-eluting stent has shown superiority over Xience.
Read more

[Articles] A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial
The sirolimus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. MiStent seems a reasonable alternative to other stents in clinical practice.
Read more

[Articles] Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
VRC5283 was well tolerated and has advanced to phase 2 efficacy testing.
Read more

[Articles] Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
The ZPIV candidate was well tolerated and elicited robust neutralising antibody titres in healthy adults.
Read more

[Comment] Tradition and innovation in development of a Zika vaccine
In response to the urgent need for a vaccine to prevent congenital syndromes associated with Zika virus, the scientific community has responded swiftly. Several vaccine technologies are in development. In The Lancet, Kayvon Modjarrad and colleagues1 and Martin R Gaudinski and colleagues2 report results of phase 1 clinical trials of candidate Zika vaccines. It has been less than 2 years since the association between Zika virus infection and microcephaly was established in Recife, Brazil,3,4 and to have multiple promising vaccine candidates in so short a time is impressive.
Read more